Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), EClinicalMedicine
A Mendelian randomization study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestry.
Gnatiuc Friedrichs L. et al, (2025), Int J Epidemiol, 54
Mortality risks in different subtypes of white-coat hypertension: implications for the diagnosis of white-coat hypertension.
de la Sierra A. et al, (2025), J Hypertens
An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression.
Donovan K. et al, (2025), Eur J Hum Genet
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY PW. et al, (2025), The Lancet Infectious Diseases
MORTALITY RISKS IN SUBTYPES OF WHITE-COAT HYPERTENSION: IMPLICATIONS FOR THE DIAGNOSIS OF WHITE-COAT HYPERTENSION
De la Sierra A. et al, (2025), Journal of Hypertension, 43, e11 - e12
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry.
de la Sierra A. et al, (2024), J Hypertens
Resistant Hypertension and Mortality: An Observational Cohort Study.
de la Sierra A. et al, (2024), Hypertension, 81, 2350 - 2356
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV. et al, (2024), BMJ Open, 14
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
A global view on kidney care.
Staplin N., (2024), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 39, ii1 - ii2
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol, 19, 1180 - 1182
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129